Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Biomarker spinout founded by Dunn School alumni holds successful flotation on AIM

Clinical Trials Innovation Research

Oxford Biodynamics, a biomarker company set up by former Dunn School researchers Dr Alexandre Akoulitchev and Dr Aroul Ramadass, completed a successful flotation on AIM, the London Stock Exchange’s international market for smaller growing companies, on 6 December 2016.

Spun out in 2007 by Oxford University Innovation, the company has commercialised technological breakthroughs in a new generation of biomarkers for cancer and other diseases.

Read more (Sir William Dunn School of Pathology website)